Our Science – Doroshow Website
James H. Doroshow, M.D.
Selected Publications |
 |
| 1)
Abrams J, Mooney M, Zweibel J, Christian M, Doroshow J. Structures Supporting Cancer Clinical Trials. In: Abeloff's Clinical Oncology. Volume 1. Philadelphia: Elsevier; 2013. In Press. [Book Chapter] |
|
| 2)
Kummar S, Murgo A, Tomaszewski J, Doroshow J. Therapeutic Targeting of Cancer Cells: Era of Molecularly Targeted Agents. In: Abeloff's Clinical Oncology. Volume 1. Philadelphia: Elsevier; 2013. In Press. [Book Chapter] |
|
| 3)
Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother. Pharmacol. 71: 981-90, 2013. [Journal] |
|
| 4)
Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH. Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-? and lipopolysaccharide in human pancreatic cancer cell lines. J. Immunol. 190: 1859-72, 2013. [Journal] |
|
| 5)
Doroshow JH, Gaur S, Markel S, Lu J, van Balgooy J, Synold TW, Xi B, Wu X, Juhasz A. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts. Free Radic. Biol. Med. 57: 162-75, 2013. [Journal] |
|
| 6)
Kummar S, Anderson L, Hill K, Majerova E, Allen D, Horneffer Y, Ivy SP, Rubinstein L, Harris P, Doroshow JH, Collins JM. First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2"-Deoxyribose in Patients with Advanced Malignancies. Clin. Cancer Res. 19: 1852-7, 2013. [Journal] |
|
| 7)
Wu Y, Antony S, Hewitt SM, Jiang G, Yang SX, Meitzler JL, Juhasz A, Lu J, Liu H, Doroshow JH, Roy K. Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody. Int. J. Oncol. 42: 1229-38, 2013. [Journal] |
|
| 8)
Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3: 68-81, 2013. [Journal] |
|
| 9)
Kummar S, Doroshow JH. Molecular targets in cancer therapy. Expert Rev Anticancer Ther. 13: 267-9, 2013. [Journal] |
|
| 10)
Park SR, Davis M, Doroshow JH, Kummar S. Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol. 10: 154-68, 2013. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/9/2013.
